Biocon, Mylan launch first insulin glargine biosimilar, Semglee in Australia
Biocon Ltd and Mylan N.V. announced the launch of Semglee (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen),... Read More
Case Study: The Mylan-Upjohn,Pfizer Merger
Pfizer, the world’s largest drugmaker, plans to combine its off-patent drug business and combine it with generic-drug maker Mylan. Pfizer shareholders would... Read More
Health Canada approves Biocon and Mylan’s trastuzumab biosimilar ‘Ogivri’ for HER2-positive cancers
Biocon and Mylan have received the clearance from Health Canada for the latter’s biosimilar Herceptin: trastuzumab co-developed under the brand name Ogivri... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Otsuka Pharmaceutical and Mylan N.V licensing deal : Otsuka grants license to Mylan to market MDR-TB drug Deltyba in India South Africa
Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan... Read More
Drug majors Mylan and Biocon’s biosimilar trastuzumab close to USFDA approval
Posted on17 Jul 2017
Comments0
Drug majors Mylan and Biocon on Friday said the US health regulator’s Oncologic Drugs Advisory Committee (ODAC) has recommended approval for their... Read More
Quick Look to Momenta, Mylan’s Phase I study of Orencia biosimilar, M834
Momenta Pharmaceuticals, Inc. and Mylan NV, announced that dosing has begun in a phase 1 study to compare the pharmacokinetics, safety and... Read More
Mylan to acquire Swedish Drug Maker Meda for $7.2 Billion
Acquring Company: Mylan Acquired Company: Meda Deal Value: $7.2 billion Deal Expected Outcome : The combination of Mylan and Meda will create a... Read More
Mylan NV and Momenta Pharmaceuticals Inc. deal to develop and commercialize six biosimilars jointly
Mylan NV and Momenta Pharmaceuticals Inc. said Friday they would jointly develop and commercialize six biosimilars. Mylan will make an upfront cash... Read More
Mylan, Gilead Ink Deal for TAF-based HIV Drugs
Mylan Inc. and Gilead Sciences, Inc. have entered into an agreement under which Mylan has licensed the non-exclusive rights to manufacture and... Read More